MDI Therapeutics

Arxx Therapeutics

This biotechnology firm develops monoclonal antibody therapies for patients suffering from chronic inflammatory and fibrotic diseases.

Promedior

This biotechnology company develops drug therapies to treat rare fibrotic diseases for patients with conditions such as idiopathic pulmonary fibrosis and myelofibrosis.

Alevin Therapeutics

This biotechnology company develops small molecule integrin inhibitors to treat patients with life-threatening fibrotic diseases, including lung, liver and kidney conditions.

Celea Therapeutics

The company develops deupirfenidone, an antifibrotic medicine for patients with idiopathic pulmonary fibrosis and other serious respiratory diseases.

AgomAb Therapeutics

This biopharmaceutical company develops therapies to treat fibrotic and inflammatory diseases for patients with conditions such as Crohn's disease and pulmonary fibrosis.

Morphic Therapeutic

This biopharmaceutical company develops oral integrin therapies for patients with serious chronic diseases, including autoimmune conditions, fibrosis, and inflammatory bowel disease.

Melius Pharma

The company develops pharmaceutical treatments for chronic cough in patients with idiopathic pulmonary fibrosis.

Forth Therapeutics

This biotechnology company develops precision therapeutics for patients with organ fibrosis using a multi-omic discovery platform and human liver disease datasets.